Summary A total of 142 patients With multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine al., 1984). We reported the early results of a modified VAD regimen given to newly diagnosed, relapsed and refractory patients in 1987. The response rate was 80% for previously untreated patients and 50% for relapsed or refractory patients (Anderson et al.. 1987) . From 1984 the VAD regimen has become our standard remission induction therapy for multiple myeloma.
Before the use of chemotherapy for multiple myeloma the median survival was 7 months from the date of symptomatic therapy. Melphalan and prednisolone combination therapy was associated with a 50% response rate and a median survival of 24 months. (Woodruff. 1981) . The addition of cyclophosphamide in our hands gave a modest improvement in response rate (57%) and was associated with a median survival of 27 months. The high response rate of myeloma to VAD (vincristine, doxorubicin and dexamethasone), a nonalkylating agent-based regimen, was an exciting development for patients with relapsed and refractory myeloma (Barlogie et al., 1984) . We reported the early results of a modified VAD regimen given to newly diagnosed, relapsed and refractory patients in 1987. The response rate was 80% for previously untreated patients and 50% for relapsed or refractory patients (Anderson et al.. 1987) . From 1984 the VAD regimen has become our standard remission induction therapy for multiple myeloma.
The aim of this paper is to report the results of the treatment of multiple myeloma using VAD as remission induction therapy in this institution.
Materials and meds
All patients with multiple myeloma referred to our unit were treated with VAD unless serious concurrent medical conditions precluded the use of high-dose dexamethasone (uncontrolled cardiac failure, unstable diabetes or chronic chest infection, e.g. bronchiectasis).
The staging tests for myeloma included a modified skeletal survey and bone marrow examination. Serum was taken for protein and immunoelectrophoresis and quantification of immunoglobulins. A 24 h urine specimen was collected for quantification of light chains, total protein excretion and creatinine clearance. In all cases the pathology was reviewed. Myeloma was staged according to the Durie and Salmon (1975) (Gahrton et al., 1991) .
Interferon has shown activity in multiple myeloma. Randomised trials have been conducted using interferon after patients have responded to chemotherapy in myeloma. Some have shown an advantage for maintenance interferon (Mandelli et al., 1990; Westin et al., 1991; Cunningham et al., 1993) , however, others have not (Ludwig et al., 1991) . Randomised tnrals of interferon in combination with chemotherapy have shown higher response rates in the interferon group (Bjorkholm et al. 1991; Ludwig et al., 1991) . Large, national studies are under way to address the optimal use of interferon.
New strategies are needed for improving the treatment of relapsed/refractory myeloma. Options include the use of maintenance interferon and dexamethasone (San Miguel et al., 1990; Palumbo et al., 1992) , anti-interleukin 6 monoclonal antibodies (Klein et al., 1990) , or the use of agents to reduce resistance to chemotherapy (Jonsson et al., 1992) .
CR in multiple myeloma may be as important a prognostic factor for long-term survival as in other haematological malignancies. The high response rate of untreated myeloma to VAD encourages its continued use for remission induction therapy. Our present strategy in all VAD responders under 70 years of age is to consolidate with high-dose cyclophosphamide, harvest peripheral blood stem cells and proceed to melphalan and total body irradiation with PBSCI and maintenance imterferon.
